1. Scrip
  2. >>New Products

This Means War: Identical Labels Recommended For Gilead, AbbVie's HCV Drugs In Europe

 
• By Lucie Ellis-Taitt

AbbVie and Gilead have won positive recommendations in Europe and matching eight-week dosing labels for their latest hepatitis C combination therapies, Maviret and Vosevi – now it's all about the price.

Hepatitis C virus
Gilead Manages To Match AbbVie's Hep C Label In Europe Despite Trial Miss

AbbVie Inc. and Gilead Sciences Inc. have secured positive recommendations for approval of their respective new hepatitis C drugs, Maviret and Vosevi, and now it is game on in Europe for the two companies to see who can secure the best reimbursement deals and convince physicians to prescribe their therapy.

AbbVie's positive recommendation from the European Medicines Agency's scientific committee, the CHMP, was expected for the use of Maviret as an eight-week regimen in all treatment-naïve non-cirrhotic hepatitis C patients (the majority of patients going forward) regardless of genotype

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.